08247 BIOSINO BIO-TEC
- 0.900
- -0.020-2.17%
BIOSINO BIO-TEC News
Zhongsheng Beikong Biotechnology (08247.HK): Li Jifeng Resigns as Shareholder Representative Supervisor and Chairman of the Supervisory Board
Gelonghui, April 26, 丨 Zhongsheng Beikong Biotechnology (08247.HK) announced that on April 26, 2024, Li Jifeng has resigned as the representative supervisor of the company's shareholders and the chairman of the company's board of supervisors due to other work arrangements.
Zhongsheng Beikong Biotechnology (08247) announced its 2023 annual results. Shareholders should account for a loss of 11.648 million yuan
Zhongsheng Beikong Biotechnology (08247) announced its annual results for the year ended December 31, 2023, with revenue reaching...
BIOSINO BIO-TEC: Annual Report 2023
BIOSINO BIO-TEC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Zhongsheng Beijing Holdings Biotechnology (08247) issued a profit warning. The net loss for the year is expected to increase from 18 million yuan to 22 million yuan over the same period last year
According to the Zhitong Finance App, Zhongsheng Beijing Holdings Biotechnology (08247) issued an announcement. It is expected that the Group will have a net loss of RMB 18 million to RMB 22 million for the year ended December 31, 2023, while net profit of about RMB 14.202 million for the year ended December 31, 2022. According to the announcement, the expected losses during the reporting period were mainly due to changes in domestic and foreign public health prevention and control policies, a decline in market demand; and a decrease in the Group's gross profit due to falling product prices due to centralized procurement in the industry; and the Group's superior products (such as flow cytometry and
BIOSINO BIO-TEC: PROFIT WARNING
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Zhongsheng Beikong Biotechnology (08247) released the first three quarter results, and shareholders accounted for losses of 5.993 million yuan
According to the Zhitong Finance App, Zhongsheng Beikong Biotechnology (08247) released results for the nine months ended September 30, 2023, with operating income of 2106 million yuan (RMB, same below), a year-on-year decrease of 23.6%; parent company owners accounted for losses of 5.993 million yuan, profit for the same period last year; basic loss of 0.041 yuan per share. During the reporting period, the company completed a total of 42 types of II products, including the glycated serum protein assay kit (NBT method), and 7 Class III products, including the herpes simplex virus type 1 IgG antibody test kit (chemiluminescence method), were changed and registered. α-L-
BIOSINO BIO-TEC: Third Quarterly Report 2023
BIOSINO BIO-TEC: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2023
Intraday quick overview | The three major indices rushed higher and fell, and the index rose slightly; pharmaceutical stocks and domestic housing stocks had the highest gains, Pharmaceuticals Biotech rose more than 5%, and Country Garden rose more than 4%
Most of the Internet of Technology stocks rose, Kuaishou and Tencent rose nearly 2%; most auto stocks fell; Xiaopeng Motor fell by more than 4%, and Zero Sports fell by more than 3%.
Can we expect a large-scale market? Pharmaceutical funds have rebounded across the board. What I'm most concerned about is actually...
What pharmaceutical fund managers are most worried about now is whether non-pharmaceutical funds and top players will think about it again in the midst of a ferocious pharmaceutical backlash.
The Hong Kong Stock Exchange Index fell nearly 6% in the third quarter, but public funds bucked the trend and increased their positions in this sector
① What was the overall position of public funds in the third quarter? ② What do you think of the Hong Kong stock market in the future?
Opinion | Public investment in Hong Kong stocks in the third quarter: bucked the trend and increased positions, and biomedical holdings increased significantly
Overall, Hong Kong stocks weakened in the third quarter. In particular, after August, the trend declined. The index once hit a new low during the year, and there was also a clear outflow of foreign capital. However, southbound capital continued the buying trend, in stark contrast to the continued weakness of northbound capital.
Zhongsheng Beikong Biotechnology (08247): Yang Peng appointed as non-executive director and vice chairman
Zhongsheng Beikong Biotechnology (08247) announced that Mr. Yang Peng has been appointed as the company's non-executive director and vice chairman,...
Intraday quick overview | Hong Kong stocks weakened again, with the Codex falling nearly 2%; Science and Technology Network stocks and pharmaceutical stocks had the highest declines, and COSCO Haineng rose nearly 5% against the market
The three major indices weakened once again. As of press release, the Hang Seng Index fell 1.12% and the Codex fell 1.66%; Science and Technology Network stocks generally fell, Kuaishou fell nearly 4%, Meituan and Bilibili fell about 3%, NetEase, Tencent, and Ali fell about 2%, Baidu and Xiaomi fell more than 1%; pharmaceutical stocks weakened, Lepu Biotech fell nearly 11%, and BeiGene fell nearly 6%.
Analysis
Price Target
No Data
